Advertisement

Topics

Clovis' Rubraca achieves 44 percent objective response rate in prostate cancer study https://www.firstwordpharma.com/node/1598474  $CLVS #ESMO18

08:09 EDT 19 Oct 2018 | FirstWord Pharma

Clovis' Rubraca achieves 44 percent objective response rate in prostate cancer study https://www.firstwordpharma.com/node/1598474 

Original Article: Clovis' Rubraca achieves 44 percent objective response rate in prostate cancer study https://www.firstwordpharma.com/node/1598474  $CLVS #ESMO18

NEXT ARTICLE

More From BioPortfolio on "Clovis' Rubraca achieves 44 percent objective response rate in prostate cancer study https://www.firstwordpharma.com/node/1598474  $CLVS #ESMO18"

Advertisement
Quick Search
Advertisement
Advertisement